Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function



Rating:

Share or cite this content

Citations should be made in the following way:
H. Schäfer (Bochum, Germany), M. Barker (Berlin, Germany), P. Follmann (Kaiserslautern, Germany), A. Günther (Berlin, Germany), P. Kaiser-Labusch (Bremen, Germany), S. Kerzen (Regensburg, Germany), C. Schmidt (Dinslaken, Germany), K. Schütz (Hannover, Germany), F. Stehling (Essen, Germany), N. Timmesfeld (Bochum, Germany), P. Vöhringer (Karlsruhe, Germany), F. Brinkmann (Bochum, Germany). Fate or missed opportunities - challenges in diagnosing paediatric drug resistant tuberculosis in Germany. 3149

Member's Comments

No comment yet.

Related content which might interest you: Management of drug resistant pulmonary TB. New problems and perspectives Source: Annual Congress 2009 - Multi/extensively-drug resistant tuberculosis Year: 2009 Therapeutic drug monitoring practice in patients with active tuberculosis: assessment of opportunities Source: Eur Respir J, 57 (1) 2002349; 10.1183/13993003.02349-2020 Year: 2021 Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges Source: Eur Respir J 2016; 48: 938-943 Year: 2016 Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Source: Eur Respir J 2013; 42: 1449-1453 Year: 2013 Advances in the diagnosis of mycobacteria infections and challenges of drug susceptibility testing Source: International Congress 2019 – New guidelines for treatment of nontuberculous mycobacterial pulmonary disease Year: 2019 Non-tuberculous mycobacterial disease in patients who were referred as MDR-TB in resource limited settings: need for more rapid identification Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 Will clinicians keep their place in modern management of tuberculosis? Source: Eur Respir J 2001; 18: Suppl. 33, 474s Year: 2001 Facilities for treating multidrug-resistant tuberculosis (MDRTB) in Europe Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology Year: 2016 Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity? Source: Eur Respir J, 49 (5) 1700738; 10.1183/13993003.00738-2017 Year: 2017 Tuberculosis: cost of illness in Germany Source: Eur Respir J 2012; 40: 143-151 Year: 2012 WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update Source: Eur Respir J 2011; 38: 516-528 Year: 2011 Innovative tools for diagnosis and prevention of paediatric tuberculosis Source: International Congress 2019 – Recent developments and future perspectives in the diagnosis and treatment of tuberculosis Year: 2019 Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives Source: Eur Respir Rev, 28 (152) 190035; 10.1183/16000617.0035-2019 Year: 2019 TB "cross-border" - a new challenge in tuberculosis management Source: Virtual Congress 2020 – Tuberculosis and society Year: 2020 Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 MDR-TB management: what is new? Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination Year: 2012 Challenges and perspectives for improved management of HIV/Mycobacterium tuberculosis co-infection Source: Eur Respir J 2010; 36: 1242-1247 Year: 2010 Medico-surgical considerations when looking for treatment for multidrug-resistant TB Source: Eur Respir J 2002; 20: Suppl. 38, 361s Year: 2002 Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015